The pharmaceutical company currently has several promising treatments in development for gastroenterological, dermatological, and cardiological conditions.
A survey commissioned by Bristol Myers Squibb reveals healthcare providers are confident that immunotherapy can positively impact earlier-stage cancers.
The pharma giant and the clinical-stage drug developer will join on a pilot study investigating a candidate’s potential in overcoming resistance of a cancer drug.